levoleucovorin

Manufacturer
Gland Pharma Limited
Effective date
2020-12-01
Label type
Human Prescription Drug Label
Version
5
Source
full-release
Hydrated at
2026-05-31 20:34:03

Label at a glance#

Productlevoleucovorin
Active ingredientLEVOLEUCOVORIN CALCIUM
Label structure14 sections

Indications and uses

Levoleucovorin injection is indicated for: rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients. the treatment of adults with metastatic colorectal cancer in combination with fluorouracil. Limitations of Use Levoleucovorin injec...

Storage and handling

Levoleucovorin injection is a sterile clear pale yellow color solution in a single-dose vial available as:                                        175 mg/17.5 mL solution – NDC 68083-278-01                                        250 mg/25 mL solution – NDC 68083-279-01 Store in refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light. Store in carton until contents are used. Manufactured by: Gland Pharma Limit...

Label contents#

Full prescribing information#

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION


Levoleucovorin injection is indicated for:

  • rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma.
  • diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients.
  • the treatment of adults with metastatic colorectal cancer in combination with fluorouracil.

Limitations of Use

Levoleucovorin injection is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin B12, because of the risk of progression of neurologic manifestations despite hematologic remission.



2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

2.1 Important Use Information

Spl Unclassified Section


Levoleucovorin injection is indicated for intravenous administration only. Do not administer intrathecally.


2.2 Co-administration of Levoleucovorin Injection with other agents

Spl Unclassified Section


Due to the risk of precipitation, do not co-administer levoleucovorin injection with other agents in the same admixture.

2.5 Dosage in Combination with Fluorouracil for Metastatic Colorectal Cancer

Spl Unclassified Section


The following regimens have been used for the treatment of colorectal cancer:

  • Levoleucovorin injection 100 mg/m2 by intravenous injection over a minimum of 3 minutes, followed by fluorouracil at 370 mg/m2 by intravenous injection, once daily for 5 consecutive days.
  • Levoleucovorin injection 10 mg/m2 by intravenous injection, followed by fluorouracil 425 mg/m2 by intravenous injection, once daily for 5 consecutive days.

Administer fluorouracil and levoleucovorin  injection separately to avoid the formation of a precipitate.

This five-day course may be repeated every 4 weeks for 2 courses, then every 4 to 5 weeks, if the patient has recovered from the toxicity from the prior course. Do not adjust levoleucovorin injection dosage for toxicity.


Refer to fluorouracil prescribing information for information on fluorouracil dosage and dosage modifications for adverse reactions.

2.6 Preparation for Administration

Spl Unclassified Section


  

  • Levoleucovorin contains no preservative. Observe strict aseptic technique during reconstitution of the drug product. Discard unused portion.
  • Levoleucovorin solutions may be further diluted to concentrations of 0.5 mg/mL in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. Do not store the product diluted using 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP for more than 4 hours at room temperature.
  • Visually inspect the diluted solution for particulate matter and discoloration prior to administration. Do not use if cloudiness or precipitate is observed.
  • Inject no more than 16 mL of levoleucovorin injection (160 mg of levoleucovorin) intravenously per minute, because of the calcium content of the levoleucovorin solution.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

  • Injection: 175 mg/17.5 mL (10 mg/mL) or 250 mg/25 mL (10 mg/mL) of levoleucovorin sterile clear pale yellow color solution in a single-dose vial.

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION


Levoleucovorin is contraindicated in patients who have had severe hypersensitivity to leucovorin products, folic acid or folinic acid [see Adverse Reactions (6.2)].

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Hypercalcemia

Spl Unclassified Section


Because of the calcium content of the levoleucovorin solution, inject no more than 16 mL (160 mg of levoleucovorin) intravenously per minute.



5.2 Increased Gastrointestinal Toxicities with Fluorouracil

Spl Unclassified Section


Leucovorin products increase the toxicities of fluorouracil [see Drug Interactions (7)]. Gastrointestinal toxicities, including stomatitis and diarrhea, occur more commonly and may be of greater severity and of prolonged duration. Deaths from severe enterocolitis, diarrhea, and dehydration have occurred in elderly patients receiving weekly d,l-leucovorin and fluorouracil.


Monitor patients for gastrointestinal toxicities. Do not initiate or continue therapy with levoleucovorin and fluorouracil in patients with symptoms of gastrointestinal toxicity until those symptoms have resolved. Monitor patients with diarrhea until resolved, as rapid deterioration leading to death can occur.

5.3 Drug Interaction with Trimethoprim-Sulfamethoxazole

Spl Unclassified Section


The concomitant use of d,l-leucovorin with trimethoprim-sulfamethoxazole for the acute treatment of Pneumocystis jiroveci pneumonia in patients with HIV infection was associated with increased rates of treatment failure and morbidity [see Drug Interactions (7)].

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following clinically significant adverse reactions are described elsewhere in the labeling:  

6.1 Clinical Trials Experience

Spl Unclassified Section

 Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
High-Dose Methotrexate Therapy
Table 2 presents the frequency of adverse reactions which occurred during the administration of 58 courses of high-dose methotrexate 12 grams/m2 followed by levoleucovorin rescue for osteosarcoma in 16 patients aged 6 to 21 years. Most patients received levoleucovorin 7.5 mg every 6 hours for 60 hours or longer, beginning 24 hours after completion of methotrexate administration.
Table 2: Adverse Reactions with High-Dose Methotrexate Therapy


 
Adverse Reactions
Levoleucovorin
n = 16
All Grades
 (%)
Grades 3 to 4
(%)

Gastrointestinal
Stomatitis
38
6
Vomiting
38
0
Nausea
19
0
Diarrhea
6
0
Dyspepsia
6
0
Typhlitis
6
6
Respiratory
Dyspnea
6
0
Skin and Appendages
Dermatitis
6
0
Other
Confusion
6
0
Neuropathy
6
0
Renal function abnormal
6
0
Taste perversion
6
0

Combination with Fluorouracil in Colorectal Cancer


Table 3 presents the frequency of adverse reaction which occurred in 2 arms of a randomized controlled trial conducted by the North Central Cancer Treatment Group (NCCTG) in patients with metastatic colorectal cancer. The trial failed to show superior overall survival with fluorouracil + levoleucovorin compared to fluorouracil + d,l-leucovorin. Patients were randomized to fluorouracil 370 mg/m2 intravenously and levoleucovorin 100 mg/m2 intravenously, both daily for 5 days, or to fluorouracil 370 mg/m2 intravenously and d,l-leucovorin 200 mg/m2 intravenously, both daily for 5 days. Treatment was repeated week 4 and week 8, and then every 5 weeks until disease progression or unacceptable toxicity.

Table 3: Adverse Reactions Occurring in ≥ 10% of Patients in Either Arm



Adverse Reaction
Levoleucovorin/
fluorouracil
n=318
d,l-Leucovorin/
fluorouracil
n=307
Grades 1 to 4
(%)
Grades 3 to 4
(%)
Grades 1 to 4
(%)
Grades 3 to 4
(%)
Gastrointestinal Disorders
Stomatitis
72
12
72
14
Diarrhea
70
19
65
17
Nausea
62
8
61
8
Vomiting
40
5
37
6
Abdominal Pain1
14
3
19
3
General Disorders
Asthenia/Fatigue/Malaise
29
5
32
11
Skin Disorders
Dermatitis
29
1
28
1
Alopecia
26
0.3
28
1
Metabolism and Nutrition
Anorexia/Decreased Appetite
24
4
25
2

1Includes abdominal pain, upper abdominal pain, lower abdominal pain, and abdominal tenderness

6.2 Postmarketing Experience

Spl Unclassified Section

The following adverse reaction have been identified during postapproval use of levoleucovorin products. Because these reactions are reported from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Dermatologic: pruritus, rash

Respiratory: dyspnea

Other: temperature change, rigors, allergic reactions

7 DRUG INTERACTIONS

DRUG INTERACTIONS SECTION

7.1 Effects of Leucovorin Products on Other Drugs

Spl Unclassified Section

Antiepileptic Drugs
Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone and increase the frequency of seizures in susceptible children. It is not known whether folinic acid has the same effects; however, both folic and folinic acids share some common metabolic pathways. Monitor patients taking folinic acid in combination with antiepileptic drugs.
Fluorouracil
Leucovorin products increase the toxicity of fluorouracil. Do not initiate or continue therapy with levoleucovorin and fluorouracil in patients with symptoms of gastrointestinal toxicity until those symptoms have resolved. Monitor patients with diarrhea until the diarrhea has resolved, as rapid deterioration leading to death can occur [see Warnings and Precautions (5.2)].
Trimethoprim-Sulfamethoxazole
The concomitant use of d,l-leucovorin with trimethoprim-sulfamethoxazole for the acute treatment of Pneumocystis jiroveci pneumonia in patients with HIV infection was associated with increased rates of treatment failure and morbidity in a placebo-controlled study [see Warnings and Precautions (5.3)].  

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

Risk Summary

There are limited data with levoleucovorin use in pregnant women. Animal reproduction studies have not been conducted with levoleucovorin.

Levoleucovorin is administered in combination with methotrexate or fluorouracil, which can cause embryo-fetal harm. Refer to methotrexate and fluorouracil prescribing information for additional information.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

8.2 Lactation

LABOR & DELIVERY SECTION

Risk Summary

There are no data on the presence of levoleucovorin in human milk or its effects on the breastfed infant or on milk production.

Levoleucovorin is administered in combination with methotrexate or fluorouracil. Refer to methotrexate and fluorouracil prescribing information for additional information.

8.4 Pediatric Use

PEDIATRIC USE SECTION

The safety and effectiveness of levoleucovorin have been established in pediatric patients for rescue after high-dose methotrexate therapy in osteosarcoma and diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination. Use of levoleucovorin in pediatric patients is supported by open-label clinical trial data in 16 pediatric patients 6 years of age and older, with additional supporting evidence from literature [see Clinical Studies (14.1)].

The safety and effectiveness of levoleucovorin have not been established for the treatment of pediatric patients with advanced metastatic colorectal cancer.

8.5 Geriatric Use

GERIATRIC USE SECTION

Clinical studies of levoleucovorin in the treatment of osteosarcoma did not include patients aged 65 and over to determine whether they respond differently from younger patients.

In the NCCTG clinical trial of levoleucovorin in combination with fluorouracil for the treatment of metastatic colorectal cancer, no overall differences in safety or effectiveness were observed between patients age 65 years and older and younger patients.


11 DESCRIPTION

DESCRIPTION SECTION

Levoleucovorin is a folate analog and the pharmacologically active levo-isomer of d,l-leucovorin. The chemical name of levoleucovorin calcium is calcium (6S)-N-{4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl] amino]benzoyl}-L-glutamate pentahydrate. The molecular formula is C20H21CaN7O7 .5H2O and the molecular weight is 601.6. The molecular structure is:


levoleucovorin-spl-structure
levoleucovorin-spl-structure

Levoleucovorin injection, for intravenous use is supplied as a sterile clear pale yellow color solution of either 175 mg levoleucovorin in 17.5 mL or 250 mg levoleucovorin in 25 mL per single-dose vial. Each mL contains 10 mg levoleucovorin (equivalent to 12.8 mg levoleucovorin calcium pentahydrate) and 8.3 mg sodium chloride. Sodium hydroxide is used for pH adjustment to pH 8.0 (6.5 to 8.5).


12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

High-Dose Methotrexate Therapy  


Levoleucovorin is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid. Levoleucovorin does not require reduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of "one-­carbon" moieties. Administration of levoleucovorin counteracts the therapeutic and toxic effects of folic acid antagonists such as methotrexate, which act by inhibiting dihydrofolate reductase.


Combination with Fluorouracil in Colorectal Cancer  

Levoleucovorin enhances the therapeutic and toxic effects of fluorouracil. Fluorouracil is metabolized to 5-fluoro-2'-­deoxyuridine-5'-monophosphate (FdUMP), which binds to and inhibits thymidylate synthase (an enzyme important in DNA repair and replication). Levoleucovorin is converted to another reduced folate, 5,10-methylenetetrahydrofolate, which acts to stabilize the binding of FdUMP to thymidylate synthase and thereby enhancing the inhibition of thymidylate synthase.



12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

The pharmacokinetics of levoleucovorin after intravenous administration of a 15 mg dose was studied in healthy subjects. The mean maximum serum total tetrahydrofolate (total-THF) concentrations was 1722 ng/mL (CV 39%) and the mean maximum serum (6S)-5-methyl-5,6,7,8-tetrahydrofolate concentrations was 275 ng/mL (CV 18%) observed around 0.9 hours post injection.

Distribution
Exploratory studies show that small quantities of systemically administered leucovorin enter the cerebrospinal fluid (CSF), primarily as its major metabolite 5-methyltetrahydrofolate (5-MTHFA).


In humans, the CSF levels of 5-MTHFA remain 1 to 3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration.
Elimination
The mean terminal half-life was 5.1 hours for total-THF and 6.8 hours for (6S)-5-methyl-5,6,7,8-tetrahydrofolate.

Drug Interaction Studies

The mean dose-normalized steady-state plasma concentrations for both levoleucovorin and 5-methyl-THF were comparable whether fluorouracil (370 mg/m2/day as an intravenous bolus) was given in combination with levoleucovorin (250 mg/m2 and 1000 mg/m2 as a continuous intravenous infusion for 5.5 days) or with d,l-leucovorin (500 mg/m2 as a continuous intravenous infusion for 5.5 days).




13 NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1 Carcinogenesis, Mutagenesis,  Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No studies have been conducted to evaluate the potential of levoleucovorin for carcinogenesis, mutagenesis and impairment of fertility.

14 CLINICAL STUDIES

CLINICAL STUDIES SECTION

14.1 Rescue after High-Dose Methotrexate Therapy in Patients with Osteosarcoma

Spl Unclassified Section

The efficacy of levoleucovorin rescue following high-dose methotrexate was evaluated in 16 patients aged 6 to 21 years who received 58 courses of therapy for osteogenic sarcoma. High-dose methotrexate was one component of several different combination chemotherapy regimens evaluated across several trials. Methotrexate 12 grams/m2 as an intravenous infusion over 4 hours was administered to 13 patients, who received levoleucovorin 7.5 mg by intravenous infusion every 6 hours for 60 hours or longer beginning 24 hours after completion of methotrexate. Three patients received methotrexate 12.5 grams/m2 intravenously over 6 hours, followed by levoleucovorin 7.5 mg by intravenous infusion every 3 hours for 18 doses beginning 12 hours after completion of methotrexate. The mean number of levoleucovorin doses per course was 18.2 and the mean total dose per course was 350 mg. The efficacy of levoleucovorin rescue following high-dose methotrexate was based on the adverse reaction profile [See Adverse Reactions (6.1)].



14.2 Metastatic Colorectal Cancer

Spl Unclassified Section


In a randomized clinical study conducted by Mayo Clinic and North Central Cancer Treatment Group (NCCTG) in patients with metastatic colorectal cancer comparing d,l-leucovorin 200 mg/m2 and fluorouracil 370 mg/m2 versus d,l-leucovorin 20 mg/m2 and fluorouracil 425 mg/m2 versus fluorouracil 500 mg/m2, with all drugs administered by intravenous infusion daily for 5 days every 28 to 35 days, response rates were 26% (p=0.04 versus fluorouracil alone), 43% (p=0.001 versus fluorouracil alone) and 10%, respectively. Respective median survival times were 12.2 months (p=0.037), 12 months (p=0.050), and 7.7 months. The low dose d,l-leucovorin regimen was associated with a statistically significant improvement in weight gain of more than 5%, relief of symptoms, and improvement in performance status. The high dose d,l-leucovorin regimen was associated with a statistically significant improvement in performance status and trended toward improvement in weight gain and in relief of symptoms but these were not statistically significant.

In a second randomized clinical study conducted by Mayo Clinic and NCCTG, the fluorouracil alone arm was replaced by a regimen of sequentially administered methotrexate, fluorouracil, and d,l-leucovorin. Response rates with d,l-leucovorin 200 mg/m2 and fluorouracil 370 mg/m2 versus d,l-leucovorin 20 mg/m2 and fluorouracil 425 mg/m2 versus sequential methotrexate and fluorouracil and d,l-leucovorin were respectively 31% (p≤0.01), 42% (p≤0.01), and 14%. Respective median survival times were 12.7 months (p≤0.04), 12.7 months (p≤0.01), and 8.4 months. There was no statistically significant difference in weight gain of more than 5% or in improvement in performance status was seen between the treatment arms.

A randomized controlled trial conducted by NCCTG in patients with metastatic colorectal cancer failed to show superiority of a regimen of fluorouracil + levoleucovorin to fluorouracil + d,l-leucovorin in overall survival. Patients were randomized to fluorouracil 370 mg/m2 intravenously and levoleucovorin 100 mg/m2 intravenously, both daily for 5 days, or to fluorouracil 370 mg/m2 intravenously and d,l-leucovorin 200 mg/m2 intravenously, both daily for 5 days. Treatment was repeated week 4 and week 8, and then every 5 weeks until disease progression or unacceptable toxicity.

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

Levoleucovorin injection is a sterile clear pale yellow color solution in a single-dose vial available as:

                                       175 mg/17.5 mL solution – NDC 68083-278-01

                                       250 mg/25 mL solution – NDC 68083-279-01


Store in refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light. Store in carton until contents are used.


Manufactured by:

Gland Pharma Limited

Pashamylaram,

Hyderabad-502 307, INDIA.

Revised: 12/2020






PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 68083-278-01  Rx only
Levoleucovorin Injection

175 mg/17.5 mL(10 mg/mL)
Container Label
levoleucovorin-spl-175-mg-containerlevoleucovorin-spl-175-mg-container

NDC 68083-278-01    Rx only
Levoleucovorin Injection
175 mg/17.5 mL(10 mg/mL)
Carton Label

 

 levoleucovorin-spl-175-mg-cartonlevoleucovorin-spl-175-mg-carton

NDC 68083-279-01    Rx only
Levoleucovorin Injection
250 mg/25 mL(10 mg/mL)
Container Label



levoleucovorin-spl-250-mg-container
levoleucovorin-spl-250-mg-container

NDC 68083-279-01    Rx only
Levoleucovorin Injection
250 mg/25 mL (10 mg/mL)
 Carton Label

 


levoleucovorin-spl-250-mg-carton
levoleucovorin-spl-250-mg-carton

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1720765LEVOleucovorin 175 MG in 17.5 mL InjectionPSN5
172076517.5 ML levoleucovorin 10 MG/ML InjectionSCD5
1720765levoleucovorin (as levoleucovorin calcium) 175 MG per 17.5 mL InjectionSY5
1720765levoleucovorin 175 MG per 17.5 mL InjectionSY5

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
LEVOLEUCOVORIN Pharmacologic Class Indexing1Indexing - Pharmacologic Class20190712

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
d5f7850a-bc65-4866-8340-2b197ae4d8caProduct name920200206
2642c4da-5f9c-4531-8406-dc7d1c3a9032Product name120190201

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
68083-278-01levoleucovorin1 in 1 CARTONINJECTION15
68083-278-01levoleucovorin17.5 mL in 1 VIALINJECTION17.55
68083-279-01levoleucovorin1 in 1 CARTONINJECTION15
68083-279-01levoleucovorin25 mL in 1 VIALINJECTION255

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
68083-278LEVOLEUCOVORIN INJECTION [GLAND PHARMA LIMITED]5Current NDC, Legacy NDC, 2 package rows20201203_dbb3613c-78a9-4a96-a766-17e7a9e8809b.zip
68083-279LEVOLEUCOVORIN INJECTION [GLAND PHARMA LIMITED]5Current NDC, Legacy NDC, 2 package rows20201203_dbb3613c-78a9-4a96-a766-17e7a9e8809b.zip

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 5 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
68083-27868083-278-01
68083-27968083-279-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A210892-001LEVOLEUCOVORIN CALCIUMLEVOLEUCOVORIN CALCIUMEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAP2018-09-14
A210892-002LEVOLEUCOVORIN CALCIUMLEVOLEUCOVORIN CALCIUMEQ 250MG BASE/25ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-14

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 2 matching rows.

Application-product, TE code table
Application-productTE code
A210892-001AP
A210892-002AP

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 90 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A210892-001LEVOLEUCOVORIN CALCIUMEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAP2018-09-14d4dbc9d85df4…
2026-11-14 07:37:172026-10A210892-002LEVOLEUCOVORIN CALCIUMEQ 250MG BASE/25ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-14d4dbc9d85df4…
2026-10-15 13:18:302026-09A210892-001LEVOLEUCOVORIN CALCIUMEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAP2018-09-14c2088c7a36db…
2026-10-15 13:18:302026-09A210892-002LEVOLEUCOVORIN CALCIUMEQ 250MG BASE/25ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-14c2088c7a36db…
2026-09-14 22:38:342026-08A210892-001LEVOLEUCOVORIN CALCIUMEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAP2018-09-1484e616aacf4f…
2026-09-14 22:38:342026-08A210892-002LEVOLEUCOVORIN CALCIUMEQ 250MG BASE/25ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-1484e616aacf4f…
2026-08-18 06:07:402026-07A210892-001LEVOLEUCOVORIN CALCIUMEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAP2018-09-14caaa826d4ba7…
2026-08-18 06:07:402026-07A210892-002LEVOLEUCOVORIN CALCIUMEQ 250MG BASE/25ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-14caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A210892-001LEVOLEUCOVORIN CALCIUMEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAP2018-09-14011fe1cb6892…
2026-02-19 14:30 UTC2026-02A210892-002LEVOLEUCOVORIN CALCIUMEQ 250MG BASE/25ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-14011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A210892-001LEVOLEUCOVORIN CALCIUMEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAP2018-09-1431067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A210892-002LEVOLEUCOVORIN CALCIUMEQ 250MG BASE/25ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-1431067a03dcf5…
2025-08-23 18:47 UTC2025-08A210892-001LEVOLEUCOVORIN CALCIUMEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAP2018-09-146a471c1ec25d…
2025-08-23 18:47 UTC2025-08A210892-002LEVOLEUCOVORIN CALCIUMEQ 250MG BASE/25ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-146a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A210892-001LEVOLEUCOVORIN CALCIUMEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAP2018-09-14fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A210892-002LEVOLEUCOVORIN CALCIUMEQ 250MG BASE/25ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-14fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A210892-001LEVOLEUCOVORIN CALCIUMEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAP2018-09-14b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A210892-002LEVOLEUCOVORIN CALCIUMEQ 250MG BASE/25ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-14b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A210892-001LEVOLEUCOVORIN CALCIUMEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAP2018-09-1403ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A210892-002LEVOLEUCOVORIN CALCIUMEQ 250MG BASE/25ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-1403ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A210892-001LEVOLEUCOVORIN CALCIUMEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAP2018-09-142680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A210892-002LEVOLEUCOVORIN CALCIUMEQ 250MG BASE/25ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-142680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A210892-001LEVOLEUCOVORIN CALCIUMEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAP2018-09-145bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A210892-002LEVOLEUCOVORIN CALCIUMEQ 250MG BASE/25ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-145bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A210892-001LEVOLEUCOVORIN CALCIUMEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAP2018-09-14d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A210892-002LEVOLEUCOVORIN CALCIUMEQ 250MG BASE/25ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-14d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A210892-001LEVOLEUCOVORIN CALCIUMEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAP2018-09-14d06236e962d9…
2024-10-29 15:01 UTC2024-10A210892-002LEVOLEUCOVORIN CALCIUMEQ 250MG BASE/25ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-14d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A210892-001LEVOLEUCOVORIN CALCIUMEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAP2018-09-1479d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A210892-002LEVOLEUCOVORIN CALCIUMEQ 250MG BASE/25ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-1479d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A210892-001LEVOLEUCOVORIN CALCIUMEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAP2018-09-14301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A210892-002LEVOLEUCOVORIN CALCIUMEQ 250MG BASE/25ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-14301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A210892-001LEVOLEUCOVORIN CALCIUMEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAP2018-09-141e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A210892-002LEVOLEUCOVORIN CALCIUMEQ 250MG BASE/25ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-141e350fbaab3a…
2024-05-31 18:47 UTC2024-05A210892-001LEVOLEUCOVORIN CALCIUMEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAP2018-09-148072bd15b7f6…
2024-05-31 18:47 UTC2024-05A210892-002LEVOLEUCOVORIN CALCIUMEQ 250MG BASE/25ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-148072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A210892-001LEVOLEUCOVORIN CALCIUMEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-145c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A210892-002LEVOLEUCOVORIN CALCIUMEQ 250MG BASE/25ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-145c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A210892-001LEVOLEUCOVORIN CALCIUMEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-145d02ea3f76ae…
2022-04-08 23:34 UTC2022-04A210892-002LEVOLEUCOVORIN CALCIUMEQ 250MG BASE/25ML (EQ 10MG BASE/ML)SOLUTION / INTRAVENOUSAPRS2018-09-145d02ea3f76ae…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 3 · 88 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A210892-001AP1d4dbc9d85df4…
2026-11-14 07:37:172026-10A210892-002AP1d4dbc9d85df4…
2026-10-15 13:18:302026-09A210892-001AP1c2088c7a36db…
2026-10-15 13:18:302026-09A210892-002AP1c2088c7a36db…
2026-09-14 22:38:342026-08A210892-001AP184e616aacf4f…
2026-09-14 22:38:342026-08A210892-002AP184e616aacf4f…
2026-08-18 06:07:402026-07A210892-001AP1caaa826d4ba7…
2026-08-18 06:07:402026-07A210892-002AP1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A210892-001AP1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A210892-002AP1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A210892-001AP131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A210892-002AP131067a03dcf5…
2025-08-23 18:47 UTC2025-08A210892-001AP16a471c1ec25d…
2025-08-23 18:47 UTC2025-08A210892-002AP16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A210892-001AP1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A210892-002AP1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A210892-001AP1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A210892-002AP1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A210892-001AP103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A210892-002AP103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A210892-001AP12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A210892-002AP12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A210892-001AP15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A210892-002AP15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A210892-001AP1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A210892-002AP1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A210892-001AP1d06236e962d9…
2024-10-29 15:01 UTC2024-10A210892-002AP1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A210892-001AP179d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A210892-002AP179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A210892-001AP1301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A210892-002AP1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A210892-001AP11e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A210892-002AP11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A210892-001AP18072bd15b7f6…
2024-05-31 18:47 UTC2024-05A210892-002AP18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A210892-001AP15c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A210892-002AP15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A210892-001AP15d02ea3f76ae…
2022-04-08 23:34 UTC2022-04A210892-002AP15d02ea3f76ae…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
levoleucovorinLEVOLEUCOVORINGland Pharma Limiteddbb3613c-78a9-4a96-a766-17e7a9e8809b2020-12-01Warnings, Adverse reactionsExact identifier
ndc (package): 68083-279-01
ndc (package): 68083-278-01
ndc (product): 68083-279
ndc (product): 68083-278
ndc11 (package): 68083027901
ndc11 (package): 68083027801
spl id: c3b9daf5-c553-46af-b651-841b43b2e706
spl set id: dbb3613c-78a9-4a96-a766-17e7a9e8809b

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.